| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | sMAP; MAP19; MASP-2; MASP1P1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human MASP2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MASP2抗体的3篇代表性文献摘要(虚构示例，仅供参考格式)：
---
1. **文献名称**：*Targeting MASP-2 with a monoclonal antibody ameliorates complement-mediated inflammatory responses in a murine sepsis model*
**作者**：Smith A, et al.
**摘要**：研究开发了一种靶向MASP-2的单克隆抗体(narsoplimab)，在小鼠败血症模型中显著抑制补体凝集素途径激活，减少炎症因子释放，改善器官损伤，为脓毒症治疗提供潜在策略。
2. **文献名称**：*Inhibition of MASP-2 reduces thrombotic microangiopathy in aHUS patients*
**作者**：Jones R, et al.
**摘要**：通过II期临床试验，发现MASP-2抗体可通过阻断补体旁路异常激活，有效缓解非典型溶血尿毒综合征(aHUS)患者的血栓性微血管病变，且安全性良好。
3. **文献名称**：*MASP-2 antibody suppresses ischemia-reperfusion injury by modulating lectin pathway activation*
**作者**：Chen L, et al.
**摘要**：在心脏缺血再灌注损伤模型中，MASP-2抗体通过选择性抑制凝集素途径，降低心肌细胞凋亡和中性粒细胞浸润，提示其在器官移植中的保护作用。
---
注：以上文献为示例性质，实际引用需以PubMed或学术数据库检索结果为准。
The MASP2 (Mannose-Associated Serine Protease 2) antibody targets a key enzyme in the lectin pathway of the complement system, a critical component of innate immunity. MASP2 is produced primarily in the liver and circulates in blood as part of multimolecular complexes with pattern recognition molecules like MBL (mannose-binding lectin), ficolins, or collectins. When these molecules bind to pathogen-associated molecular patterns (e.g., carbohydrates on microbial surfaces), MASP2 is autoactivated, cleaving complement proteins C4 and C2 to form the C3 convertase (C4b2a), which drives downstream complement activation, inflammation, and pathogen clearance.
MASP2 antibodies are used in research to study its role in immune responses and diseases linked to lectin pathway dysregulation. Overactivation of MASP2 is implicated in conditions like atypical hemolytic uremic syndrome (aHUS), ischemia-reperfusion injury, and certain autoimmune disorders. Conversely, genetic MASP2 deficiencies increase susceptibility to infections. Therapeutic anti-MASP2 antibodies (e.g., narsoplimab) are under investigation to inhibit excessive complement activation in diseases such as transplant-associated thrombotic microangiopathy. These antibodies typically block enzymatic activity or disrupt interactions with partner proteins.
As a serine protease with a unique structure (CUB1-EGF-CUB2-CCP1-CCP2-SP domains), MASP2 is also a biomarker for lectin pathway activity. Its study aids in understanding complement-related pathologies and developing targeted immunotherapies.
×
